HUM HUMANA INC

NEUTRAL Impact: 3/10 8-K
Horizon days Filed Jun 1, 2026 Processed 11d 22h ago SEC 0000049071-26-000027
8-K context-dependent: Items 7.01
Latest settled — T+5d
HUM ▲ +6.63% at T+5d
NEUTRAL call ✓ call won +6.63% · α vs SPY +9.38% · entry $328.31 → $350.08
Next anchor: T+20d in 17d
Currently $379.22 · +15.51% from $328.31 entry
Entry anchored
Jun 1, 2026
via day open
T+1d
-2.36%
call -2.36% · α -2.50%
$320.57
settled 11d ago
T+5d
+6.63%
call +6.63% · α +9.38%
$350.08
settled 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Humana filed an 8-K under Item 7.01 to reaffirm its FY 2026 guidance of at least $8.36 GAAP EPS and at least $9.00 adjusted EPS, consistent with the April 29, 2026 press release. The reaffirmation accompanies a month-long investor roadshow (June 1–30, 2026). No new financial data or changes to outlook were provided.

Actionable Insight

The reaffirmation removes near-term guidance uncertainty but provides no catalyst. Monitor the investor roadshow for any off-script commentary on Medicare Advantage enrollment trends or medical cost trends, which are the key swing factors for Humana's 2026 results.

Key Facts

  • FY 2026 GAAP EPS guidance reaffirmed at at least $8.36
  • FY 2026 adjusted (non-GAAP) EPS guidance reaffirmed at at least $9.00
  • Guidance is unchanged from the April 29, 2026 press release
  • Management is meeting investors and analysts from June 1 to June 30, 2026
  • Reconciliation: GAAP EPS $8.36 + $0.30 amortization - $0.28 put/call adjustments + $0.81 value creation initiatives - $0.19 cumulative net tax impact = adjusted EPS $9.00

Financial Impact

No new financial data; existing guidance of at least $8.36 GAAP EPS and at least $9.00 adjusted EPS for FY 2026 reaffirmed.

epsadjustedEps

Risk Factors

  • No change to guidance — any deterioration in fundamentals since April 29 is not reflected
  • GAAP EPS guidance subject to change due to ongoing value creation initiatives, per the filing
  • Reaffirmation does not address potential headwinds from Medicare Advantage rate changes or utilization trends

Market Snapshot

Exchange
NYSE
Sector
Hospital & Medical Service Plans
Analyst Consensus
30% bullish (33 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000049071-26-000027
Document: 0000049071-26-000027-index-headers.html0000049071-26-000027
Document: 0000049071-26-000027-index.html0000049071-26-000027
Document: 0000049071-26-000027.txt0000049071-26-000027
5 reports for HUM
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HUM — sortable, filterable
Type Now
Jun 1, 2026
11d ago
8-K
NEUTRAL ★ 3/10
$328.31 $350.08▲ +6.63%▲ +9.38%$379.22 (+15.51%)
Apr 10, 2026
9w ago
8-K
NEUTRAL ★ 3/10
$197.53 $209.92▲ +6.27%▲ +2.98%$379.22 (+91.98%)
Mar 6, 2026
14w ago
DEFA14A
NEUTRAL ★ 3/10
$179.09 $165.30▼ −7.70%▼ −6.17%$379.22 (+111.75%)
Mar 2, 2026
14w ago
Court Ruling
NEUTRAL ★ 4/10
$187.00 $177.72▼ −4.96%▼ −3.76%$379.22 (+102.80%)
Mar 2, 2026
14w ago
Court Ruling
BULLISH ★ 5/10
$187.00 $177.72▼ −4.96%▼ −3.76%$379.22 (+102.80%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (52h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access